🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Palvella Therapeutics, Inc. (PVLA)
NASDAQ: PVLA · Real-Time Price · USD
146.94
+1.17 (0.80%)
Nov 20, 2026, 11:55 AM EST - Market open
← View all transcripts

Status update

Nov 19, 2026

Summary

QTORIN docetaxel is being developed as a topical treatment for EMPD, aiming to deliver docetaxel to diseased skin while limiting systemic exposure. IND-enabling studies are underway, with an FDA meeting expected in H1 2027 and a Phase II study planned afterward.

Operator

day, and thank you for standing by. Welcome to the QTORIN docetaxel for extramammary Paget's disease conference call. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, Bohan Wei, Vice President of Corporate Development and New Product Planning. Please go ahead.

Bohan Wei
VP of Corporate Development and New Product Planning, Palvella Therapeutics

Thank you, operator. Good morning, and thank you for joining the Palvella Therapeutics conference call to discuss our new product candidate, QTORIN docetaxel for extramammary Paget's disease. As a reminder, our press release detailing today's announcements can be found in the investor section of our website at www.palvellatx.com. Before we begin, please note that today's remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning, and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors. The format of today's conference call will be presentation only. Additionally, as a reminder, we will not be discussing or commenting on our ongoing clinical trials.

On today's call, we are joined by Wes Kaupinen, Palvella's Founder and Chief Executive Officer, Dr. Jeff Martini, our Chief Scientific Officer, Dr. David Osborne, our Chief Innovation Officer, Dr. Seemal Desai, Founder of Innovative Dermatology and faculty at the University of Texas Southwestern Medical Center, and Steve Schroeder, an EMPD patient and Founder of the patient-led resource, MyEMPD. Now, I would like to hand the call over to Wes.

Wes Kaupinen
Founder and CEO, Palvella Therapeutics

Thanks, Bohan. Good morning, everyone, and thank you for joining us on today's call. Palvella in Finnish means to serve, and that's exactly what we're building this company to do, serve patients with serious rare diseases who have been overlooked for far too long by developing and commercializing FDA-approved therapies where none have existed before. In pursuit of this mission and vision, over the last few years, we've built a deep rare disease pipeline, and our R&D team continues to evaluate new opportunities across nearly 700 rare skin diseases and vascular anomalies, approximately 98% of which have no FDA-approved therapies. Within that large universe of rare diseases, we believe there is a particularly compelling opportunity to maximize patient impact in rare dermato-oncology, where a number of serious cancers and premalignant conditions with well-characterized underlying biology originate in and can often remain confined to the skin.

We believe these diseases are particularly well-suited to our proprietary QTORIN platform, which is designed to achieve therapeutic drug concentrations directly within diseased skin tissue while minimizing systemic exposure. In November of last year, we announced QTORIN pitavastatin for disseminated superficial actinic porokeratosis, or DSAP, a rare genetically driven skin disease characterized by precancerous lesions that can progress to invasive squamous cell carcinoma. Encouraging early real-world clinical experience with the off-label topical administration of statins has provided a strong rationale for pursuing the first FDA-approved therapy for DSAP, and we look forward to initiating our phase II study soon. Today, we are pleased to introduce QTORIN docetaxel, our third product candidate generated from the QTORIN platform for the treatment of extramammary Paget's disease, or EMPD. First, a few words about the disease. EMPD is serious.

It is a rare form of skin cancer that typically develops in some of the most sensitive areas of the body, including the genital and perianal regions. Surgery is frequently the recommended treatment, often requiring extensive tissue removal with potentially disfiguring consequences. When the cancer becomes invasive or spreads to other organs, it can be life-threatening. EMPD is rare, with an estimated more than 10,000 patients living with the disease in the United States. Today, for patients living with EMPD, the number of FDA-approved therapies is zero. Our goal at Palvella is to make that number one. One of those patients is Steve Schroeder, an EMPD patient himself and a patient advocate for others across the globe living with this disease. Steve spoke with our employees yesterday afternoon about his personal journey with EMPD.

His story is a true inspiration to all of us at Palvella, and we are grateful that he is joining us today. One of the more compelling scientific developments in EMPD has been the growing clinical experience of treating EMPD with intravenous docetaxel, a well-established and potent oncology agent. There are now more than 30 publications describing docetaxel's use in EMPD, including a recent retrospective study reporting an objective response rate of more than 50% in patients with advanced disease. That is a meaningful signal of activity in a cancer that has historically been very difficult to treat. There is an important limitation to how docetaxel has been used to date. Intravenous docetaxel has largely been used in advanced EMPD, often after the cancer has spread beyond its original site in the skin to lymph nodes or other organs. Our goal at Palvella is different.

We want to treat EMPD early and where it begins, in the skin, before the cancer has the opportunity to invade deeper tissue or spread elsewhere. Enter QTORIN. Under the leadership of Dr. Jeff Martini and Dr. David Osborne, together with Jason Carvell, a recent addition to the Palvella team, we have applied the QTORIN platform to docetaxel. Our goal is to develop a novel topical therapy capable of achieving therapeutic concentrations of this potent oncology agent directly within diseased skin while limiting systemic exposure. This is the Palvella playbook. We identify serious rare diseases with no FDA-approved therapies where the biology is well understood and existing human clinical evidence supports the therapeutic potential of a specific molecule or class of molecules. We then leverage our platform to develop novel targeted topical therapies with the goal of becoming the first FDA-approved treatment for patients who have historically had none.

At the end of October, the FDA held a public meeting on its new Rare Disease Framework Initiative, emphasizing in that meeting the importance of bringing the patient's voice into drug development early. At Palvella, listening to patients has always been central to how we develop our programs.

We incorporated qualitative patient interviews into our phase II and phase III study in microcystic lymphatic malformations and our phase II study in cutaneous venous malformations. We are bringing that same patient-focused approach to QTORIN docetaxel for EMPD. In EMPD, one of the most important voices in the patient community is Steve Schroeder. In addition to being a patient himself, Steve founded MyEMPD to connect patients, share information, and advocate for others living with this serious rare cancer. Steve is a valued partner to Palvella as we advance QTORIN docetaxel, and we are honored to have him with us today at Palvella headquarters.

Steve, thank you for your leadership, your advocacy, and your courage. I want you to know that our goal at Palvella is to be relentless in our efforts to bring the first FDA-approved therapy to you and to the thousands of other patients living with EMPD. That is our commitment. We look forward to hearing you share your perspective on what it means to live with EMPD. Steve?

Steve Schroeder
Founder, MyEMPD

Thank you, Wes. My name is Steve Schroeder. As Wes mentioned, I am an EMPD patient and founder of MyEMPD. Palvella invited me to join the call today so you could hear firsthand from a patient how devastating this disease really is and how great the unmet need is. EMPD is a skin cancer. It usually appears on the genitals and around the anus. I know this disease personally. My EMPD started on my scrotum, then it was found throughout my groin, from my perineum to my pubic area and onto my penis, then on both of my legs. I have had multiple surgeries and several skin grafts. I will never forget the pain of those procedures or the scars they left behind, which still cause me discomfort and remain a constant reminder. My story is not unusual. EMPD is a serious cancer affecting both women and men.

Most patients are diagnosed before it spreads, but once it does, survival drops sharply. Although EMPD is an underdiagnosed disease, when doctors know what to look for, it is not hard to diagnose. A biopsy takes minutes in a doctor's office and is the only way to confirm the disease. Given where it appears, many patients suffer in silence. Some never tell their own families they have cancer. We need better ways to stop this disease early. There is no FDA-approved therapy for EMPD. No drug has ever been developed specifically for this disease, not one. Once patients are finally diagnosed, they go through unimaginable surgeries, cutting away skin from the most sensitive parts of the body. Even then, the cancer frequently returns. Then it is back to surgery again and again. This community needs champions.

We need patient advocates to bring people together and make sure our voices are heard, and we need a company willing to develop a treatment we can rally around. That's why I started MyEMPD. Today, patients can find each other and know they're not alone. I've personally connected with over 1,000 people living with this disease. Researchers can now reach patients who want to be part of their work, and the community is eager to share our experiences and help move research forward.

Now, for the first time, we have a company committed to developing a treatment specifically for our disease. I'm so glad Palvella is taking this on, and our community is standing behind this effort. I look forward to joining Palvella at future FDA meetings so the patient voice is part of every conversation. Patients with EMPD deserve better. Together, we can make that happen. Thank you.

Wes Kaupinen
Founder and CEO, Palvella Therapeutics

Thank you, Steve, for sharing your experience and for bringing together a community of patients who would otherwise feel isolated, and for being an advocate for those patients around the world who are eagerly awaiting an approved therapy to treat their cancer. I would now like to introduce Dr. Seemal Desai, a board-certified dermatologist. Dr. Desai previously served as the President of the American Academy of Dermatology.

He founded and directs Innovative Dermatology in the Dallas area and teaches as a Clinical Associate Professor at UT Southwestern Medical Center. Beyond his expertise in treating EMPD, he is internationally known for his work in a number of dermatologic conditions. Dr. Desai has written hundreds of publications, and he is an Associate Editor at two journals. Dr. Desai and the Palvella leadership team will share why EMPD represents an important opportunity for novel therapeutic development. I will now hand the call over to Dr. Desai.

Seemal Desai
Founder, Innovative Dermatology

Wes, thanks very much. I am thrilled to be here today to present my personal perspective and my clinical experience on treating patients with EMPD and other rare skin cancers. I would like to start by thanking Steve for your powerful testimony on the patient experience with EMPD. I certainly want to emphasize that Steve's experience is not unique, and is consistent with what I see and have heard from patients in my own clinical practice. The physical debilitation, the isolation of living with a cancer on the most private, vulnerable parts of the body, and the frustration and unknown future of chronic recurrence. Stories like Steve's are certainly, in my clinical experience, stories that deserve better treatment options, which currently are very limited. In our clinical practice, we offer surgical removal, which, as you have heard, is painful, debilitating, and disfiguring.

Because Paget cells, which I will talk about shortly, oftentimes are recurrent and recalcitrant to treatment, surgery often has to be repeated. For me as a dermatologist and for physicians who want to treat our patients effectively, that repeated surgical cycle and lack of future knowledge on recurrence is certainly both frustrating and concerning. At present, we really do not have many other options. I can tell you from my own clinical experience and from the images you see here on today's slide that extramammary Paget's disease can present in a variety of different morphologies. In fact, usually, in the initial phases, this starts as a very nondescript, nonspecific, red, scaly, sometimes itchy or sometimes even asymptomatic, thin area on the private parts of either men or women.

What I can tell you is that in the early phases, when we see those nondescript, scaly red plaques, the differential diagnosis or what is on the top of mind could include things like psoriasis or eczema or contact dermatitis or simply frictional, not thinking neoplastic and cancerous and debilitating like EMPD. It is in these latter phases, and these images are a good representation, that show you what these red scaly plaques can look like here on the scrotum, on the vulva, and even in the perianal area. It is these more later phases where you start to see the bleeding, the ulceration, the erosion, the weeping, and even the leaking of fluid that really becomes when our differential diagnosis becomes more broad to include a cancerous process. Unfortunately, it is usually in these later phases when biopsy is usually performed to confirm the diagnosis.

In essence, what I am getting at is explaining that early intervention, even in those milder phases, is critically important to prevent something like what you see on the slide from occurring, because once this happens, treatment is very difficult. In a moment, I am going to explain that a little bit more. Before we do that, let me remind you that extramammary Paget's disease is a very rare disease, but not as rare as you would think. We see many of these cases in our clinical practice, and these cases oftentimes go underdiagnosed, as I mentioned. So the real-world prevalence, I would say, is much higher than what we reported in literature, particularly in the genital and perianal area. We currently have no FDA-approved treatment, which is why intervention early is so important.

Now, as we go to the next slide, let me show you a little bit of a schematic that kind of dives us in a little bit deeper on why these sort of red scaly plaques appear as they do. Here's a slide that shows you a graphic cross-section of the skin. This is just a 3D image showing you what's the outside of the skin all the way deeper down as we go into the muscle and the blood vessels in the body. If we look at our own skin, the outer layer of what we can touch and feel is called the epidermis. These Paget cells, which you can see on this really nice, very elegant purple close-up, this is what it looks like under the microscope.

When we take a biopsy of an early lesion or even an advanced lesion of extramammary Paget's, under the microscope, our dermatopathologists would say, you see these very nice, clear, large, what we describe as almost juicy and frothy-looking cells that have these sort of interesting nuclei and cellular structure that ultimately look quite nondescript. If you look at this picture, you'd say, "Well, that doesn't look that bad." But the challenge is that these cells, called Paget cells, which are these clear, juicy cells, oftentimes percolate and travel throughout that outer layer of the skin called the epidermis, both in sort of an east-west or lateral pattern, but in many cases can also go deeper. When they go deeper, that's when we get concerned about what we call invasion into the next layer of the skin, which is the dermis.

What happens when these cells get into the next layer in the dermis? They're much closer to blood vessels and the lymphatics, which travel through the dermis, and that's how we ultimately know these cells can cause metastatic disease and travel on the body's highway system, which is the blood and lymphatic system, causing metastatic disease. One additional thing I want to mention is that Paget cells are also tricky. The cells are present in the lesion that we see with the naked eye. If a patient comes to see me and I see a red, scaly, eroded plaque on their scrotum, I'm going to take a biopsy of that red, scaly, eroded plaque, which is where you're going to see the Paget cells.

What we don't see is that many of these cells, these tricky Paget cells, travel to the edges and travel outside of that red lesion, which makes surgical treatment, again, challenging, because when you do surgery, you remove what you can see, but you may not be capturing all of those neoplastic cells that have evaded and escaped farther out to the edges. This is why treatment based on not only symptomatology, but also treatment to prevent recurrence, as well as prevention, is extremely important. With that, I'd like to turn it over to Dr. Jeff Martini, Palvella's Chief Scientific Officer, and Dr. David Osborne, Palvella's Chief Innovation Officer. Jeff, David, over to you.

Jeff Martini
Chief Scientific Officer, Palvella Therapeutics

Thanks, Dr. Desai. At Palvella, our disease-first R&D strategy centers on selecting serious rare diseases with no FDA-approved therapies and where there is often established clinical evidence in our diseases of interest. docetaxel is an approved therapy for treating many cancers and has been used off-label, showing clinical benefit in metastatic EMPD. As shown in this slide, in a retrospective multicenter study of 138 Japanese patients with metastatic disease, IV docetaxel was effective at treating EMPD with a reported 51.6% objective response rate. However, this report also details severe dose-limiting toxicities, primarily neutropenia. We have found a large and growing evidence base, including over 30 publications supporting docetaxel's clinical benefit in EMPD. docetaxel is a drug with real-world evidence of activity in this disease. Next, I'll walk you through how it works and why delivery has been a limiting factor.

Cancer is defined by uncontrolled cell division. Docetaxel works by going after these rapidly dividing cells. As you can see on the left, it binds the microtubules that pull chromosomes apart during cell division and locks them in place. The cell can't complete mitosis, and it dies. docetaxel is highly potent. It is active against dividing cells at very low concentrations, which means a small amount of drug can have a large effect. The challenge is getting the drug to the cancer. Given intravenously, the systemic side effects are severe, neutropenia and the infection risk that comes with it, edema, and peripheral neuropathy.

The use of docetaxel in metastatic cancer is limited by these toxicities. Additionally, the lack of vasculature in the epidermis prevents efficient delivery of docetaxel to the site of disease when delivered intravenously. We have a drug that is proven, potent, and effective, held back by limited access to the epidermis. That is exactly the problem QTORIN is designed to solve. I'll now hand it over to Dr. David Osborne, our Chief Innovation Officer.

David Osborne
Chief Innovation Officer, Palvella Therapeutics

Thanks, Jeff. Since its discovery, the formulation of docetaxel has been limited by its poor water solubility, meaning that toxic excipients, such as polysorbate 80, that are linked to hypersensitivity and fluid retention are required for intravenous formulations, increasing the burden on patients during treatment. Additionally, docetaxel is considered too large for skin penetration without an enhancing vehicle. Palvella's QTORIN platform is designed to overcome these obstacles to deliver docetaxel topically into the skin.

When I first looked at EMPD, it was clear that taxanes are an effective treatment for the disease that has metastasized, but their usefulness on skin lesions was limited, and the side effect profile outweighed the benefit for these lesions when administered intravenously. Our goal was to use the QTORIN platform to develop a topical taxane capable of treating EMPD that was delivered directly to the epidermis while limiting systemic exposure.

As part of our development strategy, we conducted a comprehensive screen across a wide range of taxanes to identify the optimal candidate for treating EMPD. Each molecule was rigorously evaluated across three key dimensions: potency, skin pharmacokinetics, and formulation stability within the QTORIN platform. docetaxel emerged as a clear leader. It consistently demonstrated the strongest balance across all three: high potency, robust epidermal penetration and retention in the skin when formulated in QTORIN, and excellent chemical and formulation stability. With QTORIN docetaxel, we have achieved our formulation target product profile goals. Tunable dosing accomplished our targeted epidermal drug levels. We are now in the final stages of formulation development for QTORIN docetaxel and have initiated IND-enabling studies.

Jeff Martini
Chief Scientific Officer, Palvella Therapeutics

As you can see in this close-up of the skin, EMPD starts in the epidermis. That matters because in a healthy epidermis, the keratinocytes above the basal layer have stopped dividing. They are on their way to becoming the protective outer layer of the skin. The Paget cells are different. They sit above the basal keratinocytes and migrate to the upper epidermis, where they continue to divide. In other words, in the part of the skin where EMPD resides, the Paget cells are the main target that a drug like docetaxel is looking for. This is what QTORIN docetaxel is designed to take advantage of. It breaks the 500 Dalton barrier, allowing this large molecule into the skin, concentrating the drug in the epidermis, where it kills the dividing Paget cells. Drug levels fall off with depth, which limits exposure to the healthy basal keratinocytes deeper in the skin.

Because the drug stays in the skin rather than circulating through the body, QTORIN docetaxel is designed to avoid or minimize the systemic toxicities we see with IV delivery. We are executing the Palvella playbook with an efficient and capital-disciplined development plan to potentially bring this therapy to patients as quickly as possible. We have initiated our IND-enabling studies and expect to meet with the FDA in the first half of 2027. Following that meeting, we plan to use the 505(b)(2) pathway to start a phase II study. We believe this is possible because of our established QTORIN platform and our experienced preclinical and clinical development teams. Like our entire pipeline to date, EMPD aligns optimally with our previously stated selection criteria: serious, rare, no FDA-approved therapies, strong scientific and biological rationale, published case studies and off-label use of the drug, and a commercially attractive opportunity.

We are thrilled to be advancing QTORIN docetaxel’s development with support from key opinion leaders such as Dr. Seemal Desai, Dr. Dirk Elston, Dr. Jim Treat, Dr. Vishal Patel, and patients like Steve Schroeder and others who are pioneers and thought leaders in EMPD and other rare skin cancers. The stage is now set for us to advance this important program towards the clinic. Now I will pass it back to Wes for closing remarks.

Wes Kaupinen
Founder and CEO, Palvella Therapeutics

Thank you, Jeff. I want to thank Steve for sharing your story with all of us today. Thank you also to Dr. Desai for your clinical insights and your commitment to patients living with EMPD. I also want to recognize Jeff Martini and David Osborne for their leadership and innovation, along with two of our talented R&D researchers, Heather Sosnoski and Christiaan Noyes, whose daily research helps power our QTORIN product development engine. What you're seeing today is the Palvella strategy in action. With QTORIN docetaxel, we now have three distinct product candidates generated from our QTORIN platform, spanning five serious rare diseases with no FDA-approved therapies, each grounded in compelling science and existing human clinical evidence. We're entering a particularly exciting period for Palvella.

Next quarter, on Rare Disease Day, February 28, we have our FDA target action date for QTORIN rapamycin for microcystic lymphatic malformations, with the potential on that day for our first FDA approval. We're preparing now to start two clinical trials before year-end, a phase III study in cutaneous venous malformations and a phase II study in DSAP. Next year, we expect to complete our phase II study in angiokeratomas and report out that phase II data, and we're working to advance QTORIN docetaxel into the clinic while also planning to announce a fourth QTORIN rapamycin indication later this quarter. That's the breadth of our rare disease pipeline, and that's the pace of execution we're committed to at Palvella. Ultimately, our success at Palvella will be measured by what we accomplish for rare disease patients.

Yesterday, when Steve spoke with our employees, he shared his vision for EMPD in a few simple words, quote, "Catch it early, have a topical, it will change the world." Steve, that vision captures exactly what we're working toward with QTORIN docetaxel. Our goal is to make your vision a reality for you and for the thousands of other patients living with EMPD. That's what Palvella was built to do. Thank you all for joining us today. Operator, you may now conclude the call.

Operator

This concludes today's conference call. Thank you all for your participation. You may now disconnect.